Point of care CD19 chimeric antigen receptor (CAR) T-cells for relapsed/refractory acute myeloid leukemia (AML) with aberrant CD19 antigen expression

已完结 10 由 77 发布于 2025/1/17 15:45:30

DOI:10.1016/j.retram.2024.103471
作者：Ivetta Danylesko , Noga Shem-Tov , Ronit Yerushalmi , Elad Jacoby , Amos Toren , Roni Shouval , Orit Itzhaki , Abraham Avigdor , Avichai Shimoni , Arnon Na
文献类型：期刊论文
补充材料：只需要正文

Elsevier

Abstract：Relapsed/refractory (r/r) acute myeloid leukemia (AML) is associated with poor prognosis. CD19 is a B-cell marker, is aberrantly expressed in AML, mostly with t(8; 21)(q22; q22.1). Here we r

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:SpringerStructure and Properties of LiGaO2Crystals